CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF
The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula (I), compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/C...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
17.12.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula (I), compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.
La presente descripción se relaciona generalmente a inhibidores de señalización celular del compuesto de la formula (I), composiciones y formulaciones que comprenden los mismos, métodos, procesos y sus usos. En particular, la presente descripción proporciona inhibidores de CSF-1R que demuestran inhibición sostenida de la ruta de señalización de CSF/CSF1R con toxicidad disminuida. La presente descripción también proporciona agentes terapéuticos combinatorios supramoleculares, en donde un inhibidor de CSF-1R se combina con uno o más de un agente quimioterapéutico, un inhibidor de quinasa, y un inmunoregulador, cada uno de los cuales se conjuga opcionalmente con un lípido. La presente descripción también proporciona un método para tratar cáncer, alergia, lupus eritematoso sistémico, nefritis, Enfermedad pulmonar obstructiva crónica y funciones de macrófago anormales o cualquiera de las combinaciones de los mismos. |
---|---|
Bibliography: | Application Number: MX20180009727 |